Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest Vascular endothelial growth factor Stories

Promising Results From Pilot Study For AMD
2013-06-18 13:40:01

University of Iowa There is no cure for age-related macular degeneration, an eye disease that is the leading cause of vision loss and blindness in older Americans. Last year, the National Institutes of Health reported that two drugs injected into the eyes, Avastin and Lucentis, eased symptoms for sufferers, especially those in the advanced, “wet” stage of the disease, when blood vessels in the eye become swollen and leak fluids in the eye. Yet for some AMD patients, the two...

2013-06-18 08:30:37

VANCOUVER, June 18, 2013 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) announced today that it has completed enrollment of its Phase 2 iDEAL study evaluating the efficacy and safety after repeated injections of iCo-007 in patients with Diabetic Macular Edema (DME).  The study has shown a good safety profile with no drug-related serious adverse events to date. "The last patient was enrolled and treated on June 17," said Andrew Rae, President &...

2013-06-06 04:20:54

TARRYTOWN, N.Y., June 06, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced positive top-line results for EYLEA(®) (aflibercept) Injection from the Phase 3 MYRROR study in myopic choroidal neovascularization (mCNV). In this trial, patients receiving EYLEA at an initial dose of 2 milligrams (mg), followed by treatment on an as-needed (PRN) basis, had a mean improvement in best-corrected visual acuity (BCVA) from baseline at week 24 of...

2013-06-03 10:48:37

Results of a randomized phase III clinical trial conducted by the Radiation Therapy Oncology Group (RTOG) determined that adding bevacizumab to initial treatment for glioblastoma (GBM) did not improve patient overall survival or progression-free survival. Results were reported June 2 during the plenary session of the American Society of Clinical Oncology 2013 Annual Meeting. GBM is the most common primary malignant brain tumor in adults and, despite treatment advances in recent years, the...

2013-06-03 10:45:11

The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting, according to research led by researchers at The University of Texas MD Anderson Cancer Center. The study was presented today on the plenary session of the American Society of Clinical Oncology 2013 Annual Meeting by Mark Gilbert, M.D., professor in MD Anderson's Department of...

2013-06-03 10:43:06

Gene panel may help personalize therapy for aggressive brain tumors A new test may help identify newly diagnosed glioblastoma patients more likely to benefit from bevacizumab (Avastin®), according to new research from The University of Texas MD Anderson Cancer Center. The results of the study were presented today at the annual meeting of the American Society of Clinical Oncology. This study is associated with RTOG 0825, a large multi-center Phase III trial that evaluated the...

2013-05-20 08:27:14

SAN DIEGO, May 20, 2013 /PRNewswire/ -- TRACON Pharmaceuticals, a biopharmaceutical company that develops targeted therapies for oncology and ophthalmology, today announced multiple clinical investigations for TRC105 and the presentation of two abstracts at the 49(th) Annual Meeting of the American Society of Clinical Oncology (ASCO), held May 31 to June 4 in Chicago. TRC105, a novel monoclonal antibody to endoglin (CD105), is being studied in multiple clinical trials in combination with...

2013-05-17 10:38:40

Findings suggest VEGF inhibition via TGF-B1 may be beneficial The most common cause of failure after glaucoma surgery is scarring at the surgical site, so researchers are actively looking for ways to minimize or prevent scar formation. Previous work had suggested that vascular endothelial growth factor (VEGF) activates fibrosis, whereas VEGF inhibition results in reduced scar formation and better surgical results. In a series of studies using a rabbit model of glaucoma surgery,...

2013-05-15 08:29:45

ROCKVILLE, Md., May 15, 2013 /PRNewswire/ -- EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company, today reported financial results for the three months ended March 31, 2013. (Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO ) The Company reported a net loss for the first quarter of approximately ($1.1 million), or ($0.05) per share, compared with a net loss of ($2.5 million), or ($0.23) per share, for the same period last year. The reported net loss for the...

2013-05-14 13:20:22

Researchers at the University of California, San Diego School of Medicine and UC San Diego Moores Cancer Center report that cancers physically alter cells in the lymphatic system — a network of vessels that transports and stores immune cells throughout the body — to promote the spread of disease, a process called metastasis. The findings are published in this week's online Early Edition of the Proceedings of the National Academy of Sciences. Roughly 90 percent of all cancer...